Melanoma immunotherapy trials may not capture all toxicity dataHealioCommon Terminology Criteria for Adverse Events may not appropriately reflect immune-related adverse event severity, duration or timing, according to study results. Trials also may und… Continue reading
Express.co.uk |
Blood cancer: High doses of vitamin C could encourage stem cells to die
Express.co.uk Researchers say Vitamin C may “tell” faulty stem cells in the bone marrow to mature and die normally, instead of multiplying to cause blood cancers. They explained that certain genetic changes are known to reduce the ability of an enzyme called TET2 to … |
|
Wistar scientists develop novel immunotherapy technology for prostate cancer
EurekAlert (press release) “This is an important demonstration of the possibilities opened up for immunotherapy by DMAb technology to direct in vivo production of antibodies of major relevance to human cancer,” said David B. Weiner, Ph.D., executive vice president of The Wistar … |
AGDAILY |
Monsanto gains access to ToolGen CRISPR platform | AGDAILY
AGDAILY Monsanto and ToolGen, have reached a global licensing agreement for the use of ToolGen’s CRISPR technology platform to develop agricultural products. Monsanto (MON) Signs Deal with ToolGen for CRISPR TechnologyNasdaq |